MIAMI--(BUSINESS WIRE)--OPKO Health, Inc. (NYSE:OPK) announced the availability of the 4KscoreTM Test through its CLIA-accredited OPKO Lab in Nashville, TN. The laboratory-developed test is designed to enhance the prostate biopsy decision making process that, in the United States, leads to approximately 1 million biopsies being performed annually, with 80% of the results indicating no cancer or a low-grade cancer. The 4KscoreTM Test will help to reduce unnecessary prostate biopsies by providing information on the risk (probability) of having high-grade prostate cancer.
Help employers find you! Check out all the jobs and post your resume.